Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Predicting intrinsic clearance for drugs and drug candidates metabolized by aldehyde oxidase.

Jones JP, Korzekwa KR.

Mol Pharm. 2013 Apr 1;10(4):1262-8. doi: 10.1021/mp300568r. Epub 2013 Feb 13.

2.

Models to predict unbound intracellular drug concentrations in the presence of transporters.

Korzekwa KR, Nagar S, Tucker J, Weiskircher EA, Bhoopathy S, Hidalgo IJ.

Drug Metab Dispos. 2012 May;40(5):865-76. doi: 10.1124/dmd.111.044289. Epub 2012 Jan 25.

3.

Impact of pH on plasma protein binding in equilibrium dialysis.

Kochansky CJ, McMasters DR, Lu P, Koeplinger KA, Kerr HH, Shou M, Korzekwa KR.

Mol Pharm. 2008 May-Jun;5(3):438-48. doi: 10.1021/mp800004s. Epub 2008 Mar 18.

PMID:
18345638
4.

Use of density functional calculations to predict the regioselectivity of drugs and molecules metabolized by aldehyde oxidase.

Torres RA, Korzekwa KR, McMasters DR, Fandozzi CM, Jones JP.

J Med Chem. 2007 Sep 20;50(19):4642-7. Epub 2007 Aug 25.

PMID:
17718551
5.

Empirical regioselectivity models for human cytochromes P450 3A4, 2D6, and 2C9.

Sheridan RP, Korzekwa KR, Torres RA, Walker MJ.

J Med Chem. 2007 Jul 12;50(14):3173-84. Epub 2007 Jun 19.

6.

Inhibition of recombinant cytochrome P450 isoforms 2D6 and 2C9 by diverse drug-like molecules.

McMasters DR, Torres RA, Crathern SJ, Dooney DL, Nachbar RB, Sheridan RP, Korzekwa KR.

J Med Chem. 2007 Jul 12;50(14):3205-13. Epub 2007 Jun 9.

7.
8.

Minimal in vivo activation of CYP2C9-mediated flurbiprofen metabolism by dapsone.

Hutzler JM, Frye RF, Korzekwa KR, Branch RA, Huang SM, Tracy TS.

Eur J Pharm Sci. 2001 Aug;14(1):47-52.

PMID:
11457649
9.

An assessment of the reaction energetics for cytochrome P450-mediated reactions.

Higgins L, Korzekwa KR, Rao S, Shou M, Jones JP.

Arch Biochem Biophys. 2001 Jan 1;385(1):220-30.

PMID:
11361021
10.

Evaluation of the mechanism of aromatase cytochrome P450. A site-directed mutagenesis study.

Kao YC, Korzekwa KR, Laughton CA, Chen S.

Eur J Biochem. 2001 Jan;268(2):243-51.

11.

The human CYP3A subfamily: practical considerations.

Wrighton SA, Schuetz EG, Thummel KE, Shen DD, Korzekwa KR, Watkins PB.

Drug Metab Rev. 2000 Aug-Nov;32(3-4):339-61. Review. No abstract available.

PMID:
11139133
12.

Methoxyestradiols mediate the antimitogenic effects of estradiol on vascular smooth muscle cells via estrogen receptor-independent mechanisms.

Dubey RK, Gillespie DG, Zacharia LC, Rosselli M, Korzekwa KR, Fingerle J, Jackson EK.

Biochem Biophys Res Commun. 2000 Nov 11;278(1):27-33.

PMID:
11071850
13.

A kinetic model for the metabolic interaction of two substrates at the active site of cytochrome P450 3A4.

Shou M, Dai R, Cui D, Korzekwa KR, Baillie TA, Rushmore TH.

J Biol Chem. 2001 Jan 19;276(3):2256-62. Epub 2000 Oct 27.

14.

Use of inhibitory monoclonal antibodies to assess the contribution of cytochromes P450 to human drug metabolism.

Shou M, Lu T, Krausz KW, Sai Y, Yang T, Korzekwa KR, Gonzalez FJ, Gelboin HV.

Eur J Pharmacol. 2000 Apr 14;394(2-3):199-209.

PMID:
10771285
15.

Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9.

He M, Korzekwa KR, Jones JP, Rettie AE, Trager WF.

Arch Biochem Biophys. 1999 Dec 1;372(1):16-28.

PMID:
10562412
16.

Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil.

Tracy TS, Korzekwa KR, Gonzalez FJ, Wainer IW.

Br J Clin Pharmacol. 1999 May;47(5):545-52.

17.

The cytochrome P450 suicide inhibitor, 1-aminobenzotriazole, sensitizes rats to zymosan-induced toxicity.

Carcillo JA, Korzekwa KR, Jones GS, Parise RA, Gillespie DG, Whalen MJ, Kochanek PM, Branch RA, Kost CK Jr.

Res Commun Mol Pathol Pharmacol. 1998 Oct;102(1):57-68.

PMID:
9920346
18.
19.

Role of cDNA-expressed human cytochromes P450 in the metabolism of diazepam.

Yang TJ, Shou M, Korzekwa KR, Gonzalez FJ, Gelboin HV, Yang SK.

Biochem Pharmacol. 1998 Mar 15;55(6):889-96.

PMID:
9586962
20.

Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites.

Korzekwa KR, Krishnamachary N, Shou M, Ogai A, Parise RA, Rettie AE, Gonzalez FJ, Tracy TS.

Biochemistry. 1998 Mar 24;37(12):4137-47.

PMID:
9521735
21.

The effects of diabetes on placental aromatase activity.

McRobie DJ, Korzekwa KR, Glover DD, Tracy TS.

J Steroid Biochem Mol Biol. 1997 Sep-Oct;63(1-3):147-53.

PMID:
9449216
22.

Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid.

Sadeque AJ, Fisher MB, Korzekwa KR, Gonzalez FJ, Rettie AE.

J Pharmacol Exp Ther. 1997 Nov;283(2):698-703.

23.

Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation.

Tracy TS, Marra C, Wrighton SA, Gonzalez FJ, Korzekwa KR.

Eur J Clin Pharmacol. 1997;52(4):293-8.

PMID:
9248768
24.

Role of human hepatic cytochrome P450 1A2 and 3A4 in the metabolic activation of estrone.

Shou M, Korzekwa KR, Brooks EN, Krausz KW, Gonzalez FJ, Gelboin HV.

Carcinogenesis. 1997 Jan;18(1):207-14.

PMID:
9054608
25.

Specificity of cDNA-expressed human and rodent cytochrome P450s in the oxidative metabolism of the potent carcinogen 7,12-dimethylbenz[a]anthracene.

Shou M, Korzekwa KR, Krausz KW, Buters JT, Grogan J, Goldfarb I, Hardwick JP, Gonzalez FJ, Gelboin HV.

Mol Carcinog. 1996 Dec;17(4):241-9.

PMID:
8989918
26.

Studies of flurbiprofen 4'-hydroxylation. Additional evidence suggesting the sole involvement of cytochrome P450 2C9.

Tracy TS, Marra C, Wrighton SA, Gonzalez FJ, Korzekwa KR.

Biochem Pharmacol. 1996 Oct 25;52(8):1305-9.

PMID:
8937439
27.

Substrate probe for the mechanism of aromatic hydroxylation catalyzed by cytochrome P450.

Darbyshire JF, Iyer KR, Grogan J, Korzekwa KR, Trager WF.

Drug Metab Dispos. 1996 Sep;24(9):1038-45.

PMID:
8886617
28.

Inhibitory and noninhibitory monoclonal antibodies to human cytochrome P450 2E1.

Gelboin HV, Goldfarb I, Krausz KW, Grogan J, Korzekwa KR, Gonzalez FJ, Shou M.

Chem Res Toxicol. 1996 Sep;9(6):1023-30.

PMID:
8870991
29.

Electronic models for cytochrome P450 oxidations.

Korzekwa KR, Grogan J, DeVito S, Jones JP.

Adv Exp Med Biol. 1996;387:361-9. Review. No abstract available.

PMID:
8794230
30.

Predicting the regioselectivity and stereoselectivity of cytochrome P450-mediated reactions: structural models for bioactivation reactions.

Jones JP, Shou M, Korzekwa KR.

Adv Exp Med Biol. 1996;387:355-60. Review. No abstract available.

PMID:
8794229
31.

Predicting the rates and regioselectivity of reactions mediated by the P450 superfamily.

Jones JP, Korzekwa KR.

Methods Enzymol. 1996;272:326-35. No abstract available.

PMID:
8791792
32.

Inhibitory and non-inhibitory monoclonal antibodies to human cytochrome P450 3A3/4.

Gelboin HV, Krausz KW, Goldfarb I, Buters JT, Yang SK, Gonzalez FJ, Korzekwa KR, Shou M.

Biochem Pharmacol. 1995 Nov 27;50(11):1841-50.

PMID:
8615863
33.

Designing safer chemicals: predicting the rates of metabolism of halogenated alkanes.

Yin H, Anders MW, Korzekwa KR, Higgins L, Thummel KE, Kharasch ED, Jones JP.

Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):11076-80.

34.

Cytochrome P450 2A1, 2E1, and 2C9 cDNA-expression by insect cells and partial purification using hydrophobic chromatography.

Grogan J, Shou M, Andrusiak EA, Tamura S, Buters JT, Gonzalez FJ, Korzekwa KR.

Biochem Pharmacol. 1995 Oct 26;50(9):1509-15.

PMID:
7503803
35.

Human liver oxidative metabolism of O6-benzylguanine.

Roy SK, Korzekwa KR, Gonzalez FJ, Moschel RC, Dolan ME.

Biochem Pharmacol. 1995 Oct 26;50(9):1385-9.

PMID:
7503788
36.

Comparison of substrate metabolism by wild type CYP2D6 protein and a variant containing methionine, not valine, at position 374.

Crespi CL, Steimel DT, Penman BW, Korzekwa KR, Fernandez-Salguero P, Buters JT, Gelboin HV, Gonzalez FJ, Idle JR, Daly AK.

Pharmacogenetics. 1995 Aug;5(4):234-43.

PMID:
8528270
38.

CYP4 isozyme specificity and the relationship between omega-hydroxylation and terminal desaturation of valproic acid.

Rettie AE, Sheffels PR, Korzekwa KR, Gonzalez FJ, Philpot RM, Baillie TA.

Biochemistry. 1995 Jun 20;34(24):7889-95.

PMID:
7794900
39.
40.

Role of cytochrome P450 2C9 and an allelic variant in the 4'-hydroxylation of (R)- and (S)-flurbiprofen.

Tracy TS, Rosenbluth BW, Wrighton SA, Gonzalez FJ, Korzekwa KR.

Biochem Pharmacol. 1995 May 11;49(9):1269-75.

PMID:
7763308
41.

Isotope effect studies on the cytochrome P450 enzymes.

Korzekwa KR, Gillette JR, Trager WF.

Drug Metab Rev. 1995;27(1-2):45-59. Review.

PMID:
7641584
42.

Cytochromes P450 expression systems.

Gonzalez FJ, Korzekwa KR.

Annu Rev Pharmacol Toxicol. 1995;35:369-90. Review.

PMID:
7598499
43.

Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8.

Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ, Harris JW.

Cancer Res. 1994 Nov 1;54(21):5543-6.

44.

cDNA-directed expression of human cytochrome P450 CYP3A4 using baculovirus.

Buters JT, Korzekwa KR, Kunze KL, Omata Y, Hardwick JP, Gonzalez FJ.

Drug Metab Dispos. 1994 Sep-Oct;22(5):688-92.

PMID:
7835218
45.

Regio- and stereo-selective metabolism of phenanthrene by twelve cDNA-expressed human, rodent, and rabbit cytochromes P-450.

Shou M, Korzekwa KR, Krausz KW, Crespi CL, Gonzalez FJ, Gelboin HV.

Cancer Lett. 1994 Aug 15;83(1-2):305-13.

PMID:
8062229
46.

Mutagenesis study at a postulated hydrophobic region near the active site of aromatase cytochrome P450.

Zhou D, Cam LL, Laughton CA, Korzekwa KR, Chen S.

J Biol Chem. 1994 Jul 29;269(30):19501-8.

47.
48.

Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site.

Shou M, Grogan J, Mancewicz JA, Krausz KW, Gonzalez FJ, Gelboin HV, Korzekwa KR.

Biochemistry. 1994 May 31;33(21):6450-5.

PMID:
8204577
49.

O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4.

Relling MV, Nemec J, Schuetz EG, Schuetz JD, Gonzalez FJ, Korzekwa KR.

Mol Pharmacol. 1994 Feb;45(2):352-8. Erratum in: Mol Pharmacol 1995 Sep;48(3):568.

PMID:
8114683
50.

Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9.

Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR.

Pharmacogenetics. 1994 Feb;4(1):39-42. No abstract available.

PMID:
8004131

Supplemental Content

Loading ...
Support Center